InvestWiser

Fluicell AB

FLUINasdaq StockholmHealthcareMarket value 32 m SEK
23.00SEK −1.2%
last day · Price as of 18 November 2026

The answer first

Does Fluicell beat the market?

Yes, Fluicell has beaten the market over the last year.

Fluicell+79.7%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 90% of Nordic stocks

    • Quality98
    • Value78
    • Trend40

    No. 12 of 195 in healthcare

  • Expectations in the price

    Low expectations

    For the share to return about 9% a year from today's price, it is enough that the cash Fluicell keeps shrinks about 7% a year for 10 years.

Max for seven days

Follow Fluicell with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Fluicell

From today, at a price of 23.00 SEK. Write why you follow Fluicell, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Fluicell

Your first answer is free, no account needed.

Do you own Fluicell, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Fluicell and a few more. Free, no card.

Past year against the exchange and Super Stock
Fluicell+79.7%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Fluicell has risen 79.7% over the past year, including dividends.
  • Overall, Fluicell ranks better than 90% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.5%. The price is 99.2% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

90

Quality, value and trend together. Better than 90% of Nordic stocks.

No. 12 of 195 in healthcare

Quality98
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 11 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.13
  • Asset turnoverSales divided by everything the company owns1.03
  • Return on equityProfit divided by equity+31.1%
  • Cash conversionOperating cash flow divided by profit1.14

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value78
The price · Valuation: the multiples

High Low price: you pay little for what the company earns and owns.

No. 13 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity2.0
  • P/SPrice divided by sales1.5
  • P/EPrice divided by earnings6.3
  • P/CFPrice divided by operating cash flow5.8

The ranking is built on P/E, P/B and P/S.

Trend40
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 89 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−23.9%
  • 6 months−30.7%
  • 9 months+142.1%
  • 12 months+79.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−18.1%
3 years, per year
−28.7%
5 years, per year
−58.8%
Year to date
+130.0%
Largest fall, 3 years
−99.5%
From a peak to the bottom
From the peak now
−99.2%
How far the price is from the peak
Volatility, 1 year
113.5%
How much the price swings over a year
Beta, 1 year
0.59
How much the price moves when the market moves

Return with dividends reinvested.

About Fluicell

Fluicell AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.

See the full analysis of Fluicell.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market